重组Anti-MLH1抗体[EPR3893] (ab108622)
Key features and details
- Produced recombinantly (animal-free) for high batch-to-batch consistency and long term security of supply
- Rabbit monoclonal [EPR3893] to MLH1
- Suitable for: WB
- Knockout validated
- Reacts with: Mouse, Human
Related conjugates and formulations
概述
-
产品名称
Anti-MLH1抗体[EPR3893]
参阅全部 MLH1 一抗 -
描述
兔单克隆抗体[EPR3893] to MLH1 -
宿主
Rabbit -
经测试应用
适用于: WBmore details
不适用于: Flow Cyt,IHC-P or IP -
种属反应性
与反应: Mouse, Human
预测可用于: Rat -
免疫原
Synthetic peptide. This information is proprietary to Abcam and/or its suppliers.
-
阳性对照
- WB: HeLa, HAP1, Jurkat, 293, K562 and SH-SY5Y cell lysates.
-
常规说明
To see more of the key markers and tools you need to study the hallmarks of cancer, including genome instability and mutation, please visit the following page.
This product is a recombinant monoclonal antibody, which offers several advantages including:
- - High batch-to-batch consistency and reproducibility
- - Improved sensitivity and specificity
- - Long-term security of supply
- - Animal-free production
Our RabMAb® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMAb® patents.
性能
-
形式
Liquid -
存放说明
Shipped at 4°C. Store at -20°C. Stable for 12 months at -20°C. -
存储溶液
pH: 7.20
Preservative: 0.05% Sodium azide
Constituents: 0.1% BSA, 40% Glycerol (glycerin, glycerine), 9.85% Tris glycine, 50% Tissue culture supernatant -
Concentration information loading...
-
纯度
Tissue culture supernatant -
克隆
单克隆 -
克隆编号
EPR3893 -
同种型
IgG -
研究领域
相关产品
-
Alternative Versions
-
Isotype control
-
KO cell lines
-
KO cell lysates
-
Positive Controls
-
Recombinant Protein
应用
The Abpromise guarantee
Abpromise™承诺保证使用ab108622于以下的经测试应用
“应用说明”部分 下显示的仅为推荐的起始稀释度;实际最佳的稀释度/浓度应由使用者检定。
应用 | Ab评论 | 说明 |
---|---|---|
WB | (1) |
1/1000 - 1/10000. Detects a band of approximately 85 kDa (predicted molecular weight: 85 kDa).
|
说明 |
---|
WB
1/1000 - 1/10000. Detects a band of approximately 85 kDa (predicted molecular weight: 85 kDa). |
靶标
-
功能
Heterodimerizes with PMS2 to form MutL alpha, a component of the post-replicative DNA mismatch repair system (MMR). DNA repair is initiated by MutS alpha (MSH2-MSH6) or MutS beta (MSH2-MSH6) binding to a dsDNA mismatch, then MutL alpha is recruited to the heteroduplex. Assembly of the MutL-MutS-heteroduplex ternary complex in presence of RFC and PCNA is sufficient to activate endonuclease activity of PMS2. It introduces single-strand breaks near the mismatch and thus generates new entry points for the exonuclease EXO1 to degrade the strand containing the mismatch. DNA methylation would prevent cleavage and therefore assure that only the newly mutated DNA strand is going to be corrected. MutL alpha (MLH1-PMS2) interacts physically with the clamp loader subunits of DNA polymerase III, suggesting that it may play a role to recruit the DNA polymerase III to the site of the MMR. Also implicated in DNA damage signaling, a process which induces cell cycle arrest and can lead to apoptosis in case of major DNA damages. Heterodimerizes with MLH3 to form MutL gamma which plays a role in meiosis. -
组织特异性
Colon, lymphocytes, breast, lung, spleen, testis, prostate, thyroid, gall bladder and heart. -
疾病相关
Defects in MLH1 are the cause of hereditary non-polyposis colorectal cancer type 2 (HNPCC2) [MIM:609310]. Mutations in more than one gene locus can be involved alone or in combination in the production of the HNPCC phenotype (also called Lynch syndrome). Most families with clinically recognized HNPCC have mutations in either MLH1 or MSH2 genes. HNPCC is an autosomal, dominantly inherited disease associated with marked increase in cancer susceptibility. It is characterized by a familial predisposition to early onset colorectal carcinoma (CRC) and extra-colonic cancers of the gastrointestinal, urological and female reproductive tracts. HNPCC is reported to be the most common form of inherited colorectal cancer in the Western world, and accounts for 15% of all colon cancers. Cancers in HNPCC originate within benign neoplastic polyps termed adenomas. Clinically, HNPCC is often divided into two subgroups. Type I: hereditary predisposition to colorectal cancer, a young age of onset, and carcinoma observed in the proximal colon. Type II: patients have an increased risk for cancers in certain tissues such as the uterus, ovary, breast, stomach, small intestine, skin, and larynx in addition to the colon. Diagnosis of classical HNPCC is based on the Amsterdam criteria: 3 or more relatives affected by colorectal cancer, one a first degree relative of the other two; 2 or more generation affected; 1 or more colorectal cancers presenting before 50 years of age; exclusion of hereditary polyposis syndromes. The term 'suspected HNPCC' or 'incomplete HNPCC' can be used to describe families who do not or only partially fulfill the Amsterdam criteria, but in whom a genetic basis for colon cancer is strongly suspected.
Defects in MLH1 are a cause of mismatch repair cancer syndrome (MMRCS) [MIM:276300]; also known as Turcot syndrome or brain tumor-polyposis syndrome 1 (BTPS1). MMRCS is an autosomal dominant disorder characterized by malignant tumors of the brain associated with multiple colorectal adenomas. Skin features include sebaceous cysts, hyperpigmented and cafe au lait spots.
Defects in MLH1 are a cause of Muir-Torre syndrome (MuToS) [MIM:158320]; also abbreviated MTS. MuToS is a rare autosomal dominant disorder characterized by sebaceous neoplasms and visceral malignancy.
Note=Defects in MLH1 may contribute to lobular carcinoma in situ (LCIS), a non-invasive neoplastic disease of the breast.
Defects in MLH1 are a cause of susceptibility to endometrial cancer (ENDMC) [MIM:608089].
Note=Some epigenetic changes can be transmitted unchanged through the germline (termed 'epigenetic inheritance'). Evidence that this mechanism occurs in humans is provided by the identification of individuals in whom 1 allele of the MLH1 gene is epigenetically silenced throughout the soma (implying a germline event). These individuals are affected by HNPCC but does not have identifiable mutations in MLH1, even though it is silenced, which demonstrates that an epimutation can phenocopy a genetic disease. -
序列相似性
Belongs to the DNA mismatch repair mutL/hexB family. -
细胞定位
Nucleus. - Information by UniProt
-
数据库链接
- Entrez Gene: 4292 Human
- Entrez Gene: 17350 Mouse
- Entrez Gene: 81685 Rat
- Omim: 120436 Human
- SwissProt: P40692 Human
- SwissProt: Q9JK91 Mouse
- SwissProt: P97679 Rat
- Unigene: 195364 Human
see all -
别名
- COCA 2 antibody
- COCA2 antibody
- DNA mismatch repair protein Mlh1 antibody
see all
图片
-
All lanes : Anti-MLH1 antibody [EPR3893] (ab108622) at 1/1000 dilution
Lane 1 : Wild-type HeLa cell lysate
Lane 2 : MLH1 knockout HeLa cell lysate
Lane 3 : Jurkat cell lysate
Lane 4 : HCT116 cell lysate
Lysates/proteins at 20 µg per lane.
Performed under reducing conditions.
Predicted band size: 85 kDa
Observed band size: 85 kDaLanes 1-4: Merged signal (red and green). Green - ab108622 observed at 90 kDa. Red - loading control ab8245 observed at 37 kDa.
ab108622 Anti-MLH1 antibody [EPR3893] was shown to specifically react with MLH1 in wild-type HeLa cells. Loss of signal was observed when knockout cell line ab267223 (knockout cell lysate ab257172) was used. Wild-type and MLH1 knockout samples were subjected to SDS-PAGE. ab108622 and Anti-GAPDH antibody [6C5] - Loading Control were incubated overnight at 4°C at 1 in 1000 dilution and 1 in 20000 dilution respectively. Blots were developed with Goat anti-Mouse IgG H&L (IRDye® 800CW) preadsorbed (ab216772) and Goat Anti-Rabbit IgG H&L (IRDye® 680RD) preadsorbed (ab216777) secondary antibodies at 1 in 20000 dilution for 1 hour at room temperature before imaging.
-
All lanes : Anti-MLH1 antibody [EPR3893] (ab108622) at 1/1000 dilution
Lane 1 : Wild-type HAP1 cell lysate
Lane 2 : MLH1 knockout HAP1 cell lysate
Lane 3 : HCT116 cell lysate
Lane 4 : 293T cell lysate
Lysates/proteins at 20 µg per lane.
Predicted band size: 85 kDaLanes 1 - 4: Merged signal (red and green). Green - ab108622 observed at 88 kDa. Red - loading control, ab8245, observed at 37 kDa.
ab108622 was shown to recognize MLH1 in wild-type HAP1 cells along with additional cross-reactive bands. No band was observed when MLH1 knockout samples were examined. Wild-type and MLH1 knockout samples were subjected to SDS-PAGE. ab108622 and ab8245 (loading control to GAPDH) were diluted 1/1000 and 1/2000 and incubated overnight at 4°C. Blots were developed with Goat anti-Rabbit IgG H&L (IRDye® 800CW) preadsorbed ab216773 and Goat anti-Mouse IgG H&L (IRDye® 680RD) preadsorbed ab216776 secondary antibodies at 1/10,000 dilution for 1 hour at room temperature before imaging. -
All lanes : Anti-MLH1 antibody [EPR3893] (ab108622) at 1/1000 dilution
Lane 1 : 293 cell lysate
Lane 2 : Jurkat cell lysate
Lane 3 : K562 cell lysate
Lane 4 : SH-SY5Y cell lysate
Lysates/proteins at 10 µg per lane.
Predicted band size: 85 kDa -
All lanes : Anti-MLH1 antibody [EPR3893] (ab108622) at 1/1000 dilution
Lane 1 : Hela Cells Whole Cell Lysates
Lane 2 : HCT116 Whole Cell Lysates
Lysates/proteins at 30 µg per lane.
Secondary
All lanes : Goat Polyclonal to Rabbit IgG (HRP) at 1/2000 dilution
Developed using the ECL technique.
Performed under reducing conditions.
Predicted band size: 85 kDa
Exposure time: 30 seconds
数据表及文件
-
SDS download
-
Datasheet download
文献 (0)
ab108622 尚未被引用在任何文献中。